Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Obada Subei

Neurology Phoenix, AZ Medical Doctor

NPI 1194127464 CMS profile 4223407

3877 N 7Th St Ste 200, Phoenix, AZ 85014

Open in the dashboard

General payments

$12,230

302 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Obada Subei of Phoenix, AZ is reported in the CMS Open Payments database as having received $12,230 across 302 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,410 60
2024 General $1,267 60
2023 General $6,613 78
2022 General $1,786 95
2021 General $101 6
2020 General $14 1
2019 General $40 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Obada Subei
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Obada Subei were reported at $2,410. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Obada Subei Neurology median Middle half National median
2019 $40 $474 $118–$2,177 $163
2020 $14 $367 $82–$2,309 $114
2021 $101 $438 $104–$2,547 $132
2022 $1,786 $442 $103–$2,388 $149
2023 $6,613 $464 $119–$2,312 $160
2024 $1,267 $468 $119–$2,323 $164
2025 $2,410 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Oyster Point Pharma, Inc. $5,352 15 payments
  2. Amgen Inc. $1,819 49 payments
  3. Alexion Pharmaceuticals, Inc. $776 28 payments
  4. Biogen, Inc. $709 33 payments
  5. Horizon Therapeutics plc $626 41 payments
  6. Argenx US, Inc. $420 21 payments
  7. Mallinckrodt Hospital Products Inc. $283 9 payments
  8. Pfizer Inc. $272 13 payments
  9. AbbVie, Inc. $223 17 payments
  10. Genzyme Corporation $193 5 payments
  11. Other $1,560 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 4 payments
  2. Food and Beverage $5,945 293 payments
  3. Education $217 3 payments
  4. Travel and Lodging $67 2 payments
Products named General payments · program years 2019–2025
  1. TYRVAYA $5,352 15 payments
  2. ULTOMIRIS $639 25 payments
  3. TEPEZZA Inflammation/Rare Disease $581 39 payments
  4. TYSABRI $338 14 payments
  5. TEPEZZA Tepezza $334 26 payments
  6. VUMERITY $299 14 payments
  7. VYVGART Hytrulo $299 14 payments
  8. ACTHAR $283 9 payments
  9. NURTEC ODT $272 13 payments
  10. ZAVZPRET $250 12 payments
  11. Other $2,792 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

271

Median for Neurology: 833

Drug cost

$6,593

Median for Neurology: $202,670

Branded share of claims

0%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pyridostigmine Bromide Generic 40 $4,341
Prednisone Generic 53 $693
Nortriptyline Hcl Generic 83 $628
Gabapentin Generic 32 $469
Glycopyrrolate Generic 13 $172
Baclofen Generic 22 $167
Atorvastatin Calcium Generic 12 $72
Topiramate Generic 16 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$591,341

Of which drugs: $9,823

Medicare patients

350

Average age 74

Services billed

10,950

208 women, 142 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 55%
Ischemic heart disease 27%
Diabetes 26%
Chronic kidney disease 26%
Depression 22%
Atrial fibrillation 20%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 3,362 $323
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 21 768 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEPEZZA
  • Amgen Inc. $375
$375 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $236
$236 — —
VUMERITY
  • Biogen, Inc. $235
$235 — —
VYVGART Hytrulo
  • ARGENX US, INC. $80
$80 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record